NEOS Investment Management LLC Buys 96,425 Shares of Gilead Sciences, Inc. $GILD

04 Sep 2026, 09:37 by Michael Walen · The Markets Daily

NEOS Investment Management LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 11.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 950,430 shares of the biopharmaceutical company’s stock after buying an additional 96,425 shares during the quarter. NEOS Investment Management LLC’s holdings in Gilead Sciences were worth $120,077,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. Norges Bank acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $2,617,152,000. Legal & General Group Plc bought a new position in Gilead Sciences during the 2nd quarter worth approximately $1,316,606,000. Deutsche Bank AG bought a new position in Gilead Sciences during the 2nd quarter worth approximately $918,387,000. Finally, Boston Partners acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $517,808,000. Institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Analysts raised Gilead’s earnings forecasts and upgraded the stock to “Strong Buy.” Zacks increased its 2027 quarterly EPS estimates and lifted its full-year forecast to $9.36 from $9.30. It also raised its FY2028 estimate to $9.66 from $9.58, suggesting expectations for improving profitability. Zacks upgrade and earnings estimates
Positive Sentiment: Gilead’s latest results provided a favorable foundation for the rally. The company reported quarterly revenue of $7.80 billion, above the $7.40 billion consensus estimate, while its loss per share was narrower than expected. Revenue increased 10.6% year over year, giving investors confidence in the business despite currently negative reported earnings. Gilead post-earnings performance
Positive Sentiment: A partner-backed stomach-cancer trial reached completion, creating a potential immuno-oncology catalyst. The milestone involving Arcus-supported research could provide important future data for Gilead’s oncology strategy, although the eventual investment impact depends on trial results and regulatory progress. Gilead cancer trial milestone
Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC insider trading filing

Gilead Sciences Stock Performance

Shares of GILD stock opened at $151.22 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company’s 50 day moving average price is $136.21 and its two-hundred day moving average price is $136.42. The company has a market capitalization of $187.51 billion, a P/E ratio of -56.64 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on GILD. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Morgan Stanley decreased their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Rothschild & Co Redburn lowered their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Zacks Research raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday. Finally, Daiwa Securities Group reduced their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Read Our Latest Stock Analysis on Gilead Sciences

Insider Transactions at Gilead Sciences

In related news, CEO Daniel O’Day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the sale, the chief executive officer owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 105,000 shares of company stock worth $14,495,820. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.